FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2805940486> ?p ?o ?g. }

• W2805940486 abstract "Synovial Sarcomas (SS) are rare tumors occurring predominantly in adolescent and young adults with a dismal prognosis in advanced phases. We report a first-in-human phase I of monoclonal antibody (OTSA-101) targeting FZD10, overexpressed in most SS but not present in normal tissues, labelled with radioisotopes and used as a molecular vehicle to specifically deliver radiation to FZD10 expressing SS lesions.Patients with progressive advanced SS were included. In the first step of this trial, OTSA-101 in vivo bio-distribution and lesions uptake were evaluated by repeated whole body planar and SPECT-CT scintigraphies from H1 till H144 after IV injection of 187 MBq of 111In-OTSA-101. A 2D dosimetry study also evaluated the liver absorbed dose when using 90Y-OTSA-101. In the second step, those patients with significant tumor uptake were randomized between 370 MBq (Arm A) and 1110 MBq (Arm B) of 90Y-OTSA-101 for radionuclide therapy.From January 2012 to June 2015, 20 pts. (median age 43 years [21-67]) with advanced SS were enrolled. Even though 111In-OTSA-101 liver uptake appeared to be intense, estimated absorbed liver dose was less than 20 Gy for each patient. Tracer intensity was greater than mediastinum in 10 patients consistent with sufficient tumor uptake to proceed to treatment with 90Y-OTSA-101: 8 were randomized (Arm A: 3 patients and Arm B: 5 patients) and 2 were not randomized due to worsening PS. The most common Grade ≥ 3 AEs were reversible hematological disorders, which were more frequent in Arm B. No objective response was observed. Best response was stable disease in 3/8 patients lasting up to 21 weeks for 1 patient.Radioimmunotherapy targeting FZD10 is feasible in SS patients as all patients presented at least one lesion with 111In-OTSA-101 uptake. Tumor uptake was heterogeneous but sufficient to select 50% of pts. for 90Y-OTSA-101 treatment. The recommended activity for further clinical investigations is 1110 MBq of 90Y-OTSA-101. However, because of hematological toxicity, less energetic particle emitter radioisopotes such as Lutetium 177 may be a better option to wider the therapeutic index.The study was registered on the NCT01469975 website with a registration code NCT01469975 on November the third, 2011." @default.
• W2805940486 created "2018-06-13" @default.
• W2805940486 creator A5000823360 @default.
• W2805940486 creator A5006945230 @default.
• W2805940486 creator A5009684262 @default.
• W2805940486 creator A5019588141 @default.
• W2805940486 creator A5020024953 @default.
• W2805940486 creator A5020930348 @default.
• W2805940486 creator A5024404992 @default.
• W2805940486 creator A5025540607 @default.
• W2805940486 creator A5027371764 @default.
• W2805940486 creator A5034604079 @default.
• W2805940486 creator A5038384830 @default.
• W2805940486 creator A5042202815 @default.
• W2805940486 creator A5048784388 @default.
• W2805940486 creator A5053948279 @default.
• W2805940486 creator A5060728494 @default.
• W2805940486 creator A5060949051 @default.
• W2805940486 creator A5062090491 @default.
• W2805940486 creator A5067966229 @default.
• W2805940486 creator A5075105059 @default.
• W2805940486 creator A5079171795 @default.
• W2805940486 creator A5082459561 @default.
• W2805940486 creator A5085361216 @default.
• W2805940486 creator A5085672955 @default.
• W2805940486 date "2018-06-08" @default.
• W2805940486 modified "2023-10-15" @default.
• W2805940486 title "A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients" @default.
• W2805940486 cites W1456674939 @default.
• W2805940486 cites W1546799663 @default.
• W2805940486 cites W1977316337 @default.
• W2805940486 cites W1981280742 @default.
• W2805940486 cites W1999662775 @default.
• W2805940486 cites W2048513224 @default.
• W2805940486 cites W2053598239 @default.
• W2805940486 cites W2090257199 @default.
• W2805940486 cites W2097512974 @default.
• W2805940486 cites W2101304964 @default.
• W2805940486 cites W2105337740 @default.
• W2805940486 cites W2107373757 @default.
• W2805940486 cites W2108613323 @default.
• W2805940486 cites W2108860540 @default.
• W2805940486 cites W2122334532 @default.
• W2805940486 cites W2134731586 @default.
• W2805940486 cites W2161621282 @default.
• W2805940486 cites W2229603522 @default.
• W2805940486 cites W2294375233 @default.
• W2805940486 cites W2302508993 @default.
• W2805940486 cites W2303817381 @default.
• W2805940486 cites W2415553333 @default.
• W2805940486 cites W2476097000 @default.
• W2805940486 cites W2525124727 @default.
• W2805940486 cites W2537836937 @default.
• W2805940486 cites W2577784437 @default.
• W2805940486 doi "https://doi.org/10.1186/s12885-018-4544-x" @default.
• W2805940486 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5994021" @default.
• W2805940486 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29884132" @default.
• W2805940486 hasPublicationYear "2018" @default.
• W2805940486 type Work @default.
• W2805940486 sameAs 2805940486 @default.
• W2805940486 citedByCount "40" @default.
• W2805940486 countsByYear W28059404862018 @default.
• W2805940486 countsByYear W28059404862019 @default.
• W2805940486 countsByYear W28059404862020 @default.
• W2805940486 countsByYear W28059404862021 @default.
• W2805940486 countsByYear W28059404862022 @default.
• W2805940486 countsByYear W28059404862023 @default.
• W2805940486 crossrefType "journal-article" @default.
• W2805940486 hasAuthorship W2805940486A5000823360 @default.
• W2805940486 hasAuthorship W2805940486A5006945230 @default.
• W2805940486 hasAuthorship W2805940486A5009684262 @default.
• W2805940486 hasAuthorship W2805940486A5019588141 @default.
• W2805940486 hasAuthorship W2805940486A5020024953 @default.
• W2805940486 hasAuthorship W2805940486A5020930348 @default.
• W2805940486 hasAuthorship W2805940486A5024404992 @default.
• W2805940486 hasAuthorship W2805940486A5025540607 @default.
• W2805940486 hasAuthorship W2805940486A5027371764 @default.
• W2805940486 hasAuthorship W2805940486A5034604079 @default.
• W2805940486 hasAuthorship W2805940486A5038384830 @default.
• W2805940486 hasAuthorship W2805940486A5042202815 @default.
• W2805940486 hasAuthorship W2805940486A5048784388 @default.
• W2805940486 hasAuthorship W2805940486A5053948279 @default.
• W2805940486 hasAuthorship W2805940486A5060728494 @default.
• W2805940486 hasAuthorship W2805940486A5060949051 @default.
• W2805940486 hasAuthorship W2805940486A5062090491 @default.
• W2805940486 hasAuthorship W2805940486A5067966229 @default.
• W2805940486 hasAuthorship W2805940486A5075105059 @default.
• W2805940486 hasAuthorship W2805940486A5079171795 @default.
• W2805940486 hasAuthorship W2805940486A5082459561 @default.
• W2805940486 hasAuthorship W2805940486A5085361216 @default.
• W2805940486 hasAuthorship W2805940486A5085672955 @default.
• W2805940486 hasBestOaLocation W28059404861 @default.
• W2805940486 hasConcept C126322002 @default.
• W2805940486 hasConcept C142724271 @default.
• W2805940486 hasConcept C150903083 @default.
• W2805940486 hasConcept C197934379 @default.
• W2805940486 hasConcept C207001950 @default.
• W2805940486 hasConcept C2776910622 @default.
• W2805940486 hasConcept C2777807558 @default.
• W2805940486 hasConcept C2778256501 @default.

• next